New Haven, CTNCT04438213Now EnrollingIRB Ready

Heart Failure Clinical Trial in New Haven, CT

Access cutting-edge heart failure treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access heart failure specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart failure treatment provided free

Apply for This New Haven Location

Check if you qualify for this heart failure clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Heart Failure Study in New Haven

The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study. The proposed study is both larger and more rigorous than essentially all PK/PD studies that form the basis of current practice with loop diuretics as well as all studies looking at add-on thiazide therapy (current guideline-recommended adjuvant). The second is to generate a mechanistic understanding of the pleotropic cardio-renal factors with chronic therapy that differentiate ertugliflozin from traditional diuretics particularly in how they maintain reduced blood volume without the complication of over-diuresis and volume depletion.

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

A clinical diagnosis of chronic heart failure (either systolic or diastolic)
Chronic daily oral loop diuretic dose use
eGFR ≥20 mL/min/1.73 m2
English speaking participants only
Signed informed consent

Exclusion Criteria

Current use or plan to initiate renal replacement therapy or ultrafiltration
Significant bladder dysfunction or urinary incontinence
Inability to comply with the serial urine collection procedures
Current use of a thiazide or thiazide like diuretics or use within 5 half-lives of the drug, including metolazone
Current use of a SGLT-2 inhibitor, or in the treating provider's judgement, contraindication to be withdrawn from current use of an SGLT-2 inhibitor
Prior heart transplant, critical stenotic valvular disease or complex congenital heart
History of type 1 diabetes, diabetic ketoacidosis, "brittle" diabetes or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 3 months
History of or current urosepsis or frequent urinary tract infections
Anemia with hemoglobin \<8g/dL (due to required phlebotomy for the study)
Pregnancy or breastfeeding
Appears unlikely or unable to participate in the required study procedures, as assessed by the study PI, study coordinator, or designee (ex: clinically-significant psychiatric, addictive, or neurological disease)
Inability to give written informed consent or follow study protocol
Severe peripheral artery disease, previous amputation, or threatened amputation
Life expectancy \< 3 months

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT04438213) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in New Haven, CT

If you're searching for heart failure treatment options in New Haven, CT, this clinical trial (NCT04438213) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in New Haven, CT

See all heart failure clinical trials recruiting in New Haven — not just this study.

Browse Heart Failure Trials in New Haven

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT